Advertisement


Alfonso Bencomo Álvarez, PhD, on ALL, AML, and CML: Survival for Hispanic Patients Living Near the US/Mexico Border

AACR Virtual Annual Meeting 2020 II

Advertisement

Alfonso Bencomo Álvarez, PhD, of Texas Tech University Health Sciences Center, discusses his retrospective study of the incidence and survival for patients with hematologic malignancies residing at the United States/Mexico border. The analysis showed that 10-year survival rates for Hispanic patients with ALL, AML, and CML were significantly lower for those who lived in El Paso than for those who lived elsewhere in Texas (Abstract 4343).



Related Videos

Immunotherapy

Ralph R. Weichselbaum, MD, on Radiotherapy and Immunotherapy in Oligometastatic Disease

Ralph R. Weichselbaum, MD, of the University of Chicago Cancer Research Center, explores the question of whether radiotherapy is the principal curative treatment with immunotherapy or activates immunotherapy. He also discussed how to improve the interaction of these treatments, perhaps with vaccination, transfer of genetically engineered T cells, or checkpoint inhibitors (Session ED37).

Gynecologic Cancers

Kala Visvanathan, MD, on Ovarian Cancer: Lowering Mortality With Lipophilic Statins

Kala Visvanathan, MD, of Johns Hopkins Bloomberg School of Public Health, discusses her analysis of data from more than 10,000 women with ovarian cancer. The results suggest that atorvastatin and simvastatin, lipophilic statin cholesterol-lowering drugs, reduced ovarian cancer death rates (Abstract 5782).

Issues in Oncology

Stacey A. Fedewa, PhD, on Cancers in Younger Populations: Current Trends

Stacey A. Fedewa, PhD, of the American Cancer Society, discusses the increasing incidence rates of colorectal, breast, kidney, thyroid, uterine corpus, and cervical disease in younger patients. Data show that colorectal cancer is increasing most rapidly, while breast cancer—the most common cancer among young women­­—is rising at a slower pace (Session ED35).

Issues in Oncology

Antoni Ribas, MD, PhD, on Turning Science Into Life-Saving Care

Antoni Ribas, MD, PhD, of the University of California, Los Angeles, Jonsson Comprehensive Cancer Center, summarizes the opening plenary session that addressed epigenetics and early detection, how the aging microenvironment governs response to therapy, AI-driven precision medicine, reprogramming human T cells, and opportunities for the future.

Lung Cancer
Immunotherapy

Nasser K. Altorki, MD, on Lung Cancer: Radiotherapy and Immune Checkpoint Blockade in the Neoadjuvant Setting

Nasser K. Altorki, MD, of Weill Cornell Medical College, discusses study findings that suggest neoadjuvant low-dose focal stereotactic body radiation plus immune checkpoint blockade (ICB) is safe and causes no surgical delays in early-stage lung cancer, and that major pathologic response rates are likely to be comparable to those with chemotherapy/ICB combinations (Session ED37).

Advertisement

Advertisement




Advertisement